
JHVEPhoto/iStock Editorial via Getty Images
Capricor Therapeutics (CAPR) announced that its operating expenses are under review after the U.S. Food and Drug Administration on Friday declined to approve its cell therapy candidate Deramiocel for the second time in less than two years.
In a statement, the